Drugs / ISIS 443139
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02519036 | Aug 2015 → Nov 2017 | Huntington disease | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05686551 | Feb 2023 → May 2026 overdue | Huntington disease | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-01-18 | Ionis Pharmaceuticals | Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial ionis.com ↗ |
| 2021-03-22 | Hoffmann-La Roche | Roche provides update on tominersen programme in manifest Huntington’s disease roche.com ↗ |
| 2021-03-22 | Ionis Pharmaceuticals | Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx) ionis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 443139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02519036 ↗ |
| Known as | Tominersen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05686551 ↗ |
| Route | Intrathecal | “60 mg tominersen administered intrathecally (IT) every 16 weeks (Q16W).” NCT05686551 ↗ |